Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Remdesivir developed country price announced
On 29, June 2020 Gilead announced its global price for developed countries for remdesivir, a medicine that has shown some effect in the treatment...
Corbyn’s Compulsory Licenses. Will they work?
On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...
The Pandemic Agreement is here
In December 2021, the member states of the World Health Organization decided “to draft and negotiate a WHO convention, agreement or other international instrument...
Socially Responsible Licensing of Medical Technologies
GENEVA, SWITZERLAND: On 31 October, the World Trade Organization (WTO), the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO) held their...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
The € 7.4 billion for Covid-19 product and vaccine development needs a few strings...
On 4 May 2020, European Commission President Ursula von der Leyen hosted the Coronavirus Global Response conference, an on-line pledging event to accelerate the...
Dutch Minister of Health writes open letter to pharma, threatens to name and shame
"Dear Pharma," writes the Dutch Minister of Health, Bruno Bruins in an open letter in the daily newspaper the Volkskrant, "Last week two messages jumped...
Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations
This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...